1. Adams J, Lammer EJ (1991) Relationship between dysmorphology and neuropsychological functions in children exposed to isotretinoin (in utero). In: Fujii T, Boer GJ (eds) Functional neuroteratology of short term exposure to drugs. Teiko University Press, Tokyo, pp 159–168
2. Carter JD, Ladhani A, Ricca LR et al. (2009) A safety assessment of tumor necrosis factor antagonists during pregngancy: A review of the food and drug administration database. J Rheumatol 36 [Epub ahead of print]
3. Chambers CD, Jones KL, Johnson DL, OTIS Collaborative Research Group (2007) Pregnancy outcome following early gestational exposure to leflunomide. Birth Defects Res A (Abstract) 79: 363
4. Costedoat-Chalumeau N, Amoura Z, Duhaut P et al. (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Arthritis Rheum 48: 3207–3211
5. Diav-Citrin O, Shechtman S, Weinbaum D et al. (2008) Paroxetine and Fluoxetine in Pregnancy: a prospective, multi-center, controlled, observational study. Br J Clin Pharmacol 65: 695–705